These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 12460076)
1. From the Food and Drug Administration. JAMA; 2002 Dec; 288(21):2678. PubMed ID: 12460076 [No Abstract] [Full Text] [Related]
2. Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction. Resnick RB Ann Intern Med; 2003 Feb; 138(4):360. PubMed ID: 12585846 [No Abstract] [Full Text] [Related]
3. From the Food and Drug Administration. Schwetz BA JAMA; 2001 Sep; 286(10):1166. PubMed ID: 11559244 [No Abstract] [Full Text] [Related]
4. Office-based practice and opioid-use disorders. Clark HW N Engl J Med; 2003 Sep; 349(10):928-30. PubMed ID: 12954740 [No Abstract] [Full Text] [Related]
5. [Pegasys: FDA approved Pegasys (peginterferon alfa-2a) for the treatment of hepatitis C]. Iafolla M Sidahora; 2002; (4):8-10. PubMed ID: 12703472 [No Abstract] [Full Text] [Related]
6. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence. Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113 [No Abstract] [Full Text] [Related]
7. Treatment of adolescent opioid dependence: no quick fix. Fiellin DA JAMA; 2008 Nov; 300(17):2057-9. PubMed ID: 18984896 [No Abstract] [Full Text] [Related]
18. Treatment of chronic hepatitis C in children: is it necessary and, if so, in whom? Alisi A; Comparcola D; Nobili V J Hepatol; 2010 Apr; 52(4):472-4. PubMed ID: 20185196 [No Abstract] [Full Text] [Related]
19. Similarities and differences between REPEAT and EPIC3. Poynard T; Shiff E Ann Intern Med; 2009 Nov; 151(10):754; author reply 754-5. PubMed ID: 19920277 [No Abstract] [Full Text] [Related]
20. New pharmacological tool approved for opioid addiction. Sansovich D HIV Clin; 2004; 16(3):9-11. PubMed ID: 15366107 [No Abstract] [Full Text] [Related] [Next] [New Search]